Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus

被引：1
|
作者：
Wallace, Daniel J. [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA
来源：
CURRENT RHEUMATOLOGY REPORTS | 2013年 / 15卷 / 07期
关键词：
Biologicals; Targeted therapy; Systemic lupus erythematosus; SLE; FDA; Treatment; Cutaneous lupus; Belimumab; Epratuzumab; T cell inhibition; B-LYMPHOCYTE STIMULATOR; DOUBLE-BLIND; DISEASE-ACTIVITY; PHASE-I; MONOCLONAL-ANTIBODY; CONTROLLED-TRIAL; SAFETY; BELIMUMAB; EFFICACY; RITUXIMAB;
D O I：
10.1007/s11926-013-0337-z
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Belimumab has recently been approved, and several other types of biological therapy with different mechanisms of action are currently in phase II and III studies. This review puts these approaches in context, emphasizing mechanistic categories and clinical trial designs. Most of the promising approaches involve B cell depletion or modulation. Post-approval experience with belimumab is critically reviewed.
引用
收藏
页数：8
相关论文
共 50 条
  • [31] New treatments for systemic lupus erythematosus
    Hoyer, Bimba F.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (04): : 342 - 350
  • [32] Belimumab for the management of systemic lupus erythematosus
    Lutalo, Pamela M. K.
    D'Cruz, David P.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (07) : 957 - 963
  • [33] Belimumab for systemic lupus erythematosus - Focus on lupus nephritis
    Pluess, Marlene
    Piantoni, Silvia
    Tampe, Bjoern
    Kim, Alfred H. J.
    Korsten, Peter
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (05)
  • [34] Systemic lupus erythematosus
    Shaikh, Maliha F.
    Jordan, Natasha
    D'Cruz, David P.
    CLINICAL MEDICINE, 2017, 17 (01) : 78 - 83
  • [35] Biological therapies in systemic lupus erythematosus
    Suszek, Dorota
    Jeleniewicz, Radoslaw
    Majdan, Maria
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2012, 66 : 568 - 573
  • [36] Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus
    Jordan, Natasha P.
    D'Cruz, David P.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (10) : 1635 - 1645
  • [37] Biologics in systemic lupus erythematosus: current options and future perspectives
    Yusof, Yuzaiful Md
    Vital, Edward M.
    Emery, Paul
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (08) : 440 - 447
  • [38] Belimumab for systemic lupus erythematosus: a practice-based view
    Parodis, I.
    Axelsson, M.
    Gunnarsson, I.
    LUPUS, 2013, 22 (04) : 372 - 380
  • [39] A Systematic Review of the Economic Evaluations of Belimumab in Systemic Lupus Erythematosus
    Petrou, Panagiotis
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 27 : 32 - 40
  • [40] Emerging B-Cell Therapies in Systemic Lupus Erythematosus
    Bag-Ozbek, Ayse
    Hui-Yuen, Joyce S.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 39 - 54
12345